By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

YEAR FOUNDED:

August 5, 2013

LEADERSHIP:

Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop

JOBS:

Please click here for job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


FOLLOW JUNO:



Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO
 



Industry
Biotechnology






Company News
Juno (JUNO) To Report Full Year And Fourth Quarter 2016 Financial Results On Wednesday, March 1 2/23/2017 7:14:30 AM
With Ex-Juno (JUNO) Employees on Its Roster, Seattle's Silverback Therapeutics Files $10 Million Out of $60 Million Goal 2/15/2017 7:22:15 AM
Juno (JUNO) Appoints Corsee D. Sanders As Executive Vice President And Head Of Development Operations 1/27/2017 8:24:26 AM
Social Media Rumors of Juno (JUNO) Acquisition Cause Stock Jitters 1/25/2017 6:29:19 AM
A Look at Whether Juno (JUNO) Can Recover After Losing More Than Half Its Value in 2016 1/16/2017 6:03:42 AM
Juno (JUNO)’ And Celgene (CELG)’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation From FDA And Priority Medicines Eligibility From EMAFor Relapsed/Refractory Diffuse Large B-Cell Lymphoma 12/20/2016 12:13:45 PM
Juno (JUNO) Defeats Kite Pharma (KITE)’s Challenge To CAR T-Cell Patent 12/19/2016 9:28:48 AM
Juno (JUNO) Highlights Progress With Best-in-Class Strategy In B-Cell Malignancies At American Society of Hematology 12/7/2016 11:56:00 AM
Juno (JUNO) Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma 12/6/2016 10:45:17 AM
Juno (JUNO) Lymphoma Drug Impresses in Early Stage Study, But Fear of Cerebral Edema Looms 12/5/2016 11:09:52 AM
12345678910...
//-->